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Abstract Interstitial cystitis (IC), including bladder pain syndrome (BPS), is a chronic and debilitating
disease thatmainly affects women. It is characterized by pelvic pain associatedwith urinary
urgency, frequency, nocturia andnegative urine culture,with normal cytology. In 2009, the
Society for Urodynamics and Female Urology (SUFU) defined the term IC/BPS as “an
unpleasant sensation (pain, pressure, anddiscomfort) perceived tobe related to theurinary
bladder, associated with lower urinary tract symptoms for more than 6 weeks duration, in
the absence of infection or other identifiable causes.” This is the definition used by the
American Urological Association (AUA) in the most recent guidelines on IC/BPS. Interstitial
cystitis may be sufficiently severe to have a devastating effect on the quality of life, but it
may also be associated with moderate symptoms whose effects are less debilitating.
Although there are several clinical trials to assess oral and intravesical therapies, the
treatment for IC remains far from ideal. This systematic assessment evaluates published
randomizedclinical trials onoralmedicationsused to treat symptomsofBPS. This studywas
performed according to the preferred reporting items for systematic reviews and meta-
analyses (PRISMA)method. Two independent reviewers screened the studies to determine
their inclusion or exclusion and to perform the methodological analysis. The inclusion
criteria included randomized studiespublishedbetweenApril of 1988andApril of2016 that
used oral medications to treat symptoms of BPS or IC. According to the systematic review
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Introduction
Interstitial cystitis (IC), including bladder pain syndrome
(BPS), is a chronic and debilitating disease thatmainly affects
women. It is characterized by pelvic pain associated with
urinary urgency, frequency, nocturia and negative urine
culture, with normal cytology.1,2 There is no consensus on
the physiopathology, etiology and IC classification, resulting
in diagnoses made by clinical exclusion rather than by
objective measures. Physiopathological alterations may re-
sult in a process of epithelial cell dysfunction, C nerve fiber
activation andmast cell proliferation, ultimately leading to a
worsening condition and tissue damage, scarring, fibrosis
and neuropathic pain.2 The IC diagnosis presents several
clinical phenotypes, most likely with different combinations
of etiologies, symptom complexes and associated comorbid-
ities.3 Interstitial cystitis may be sufficiently severe to have a
devastating effect on the quality of life, but it may also be
associated with moderate symptoms whose effects are less
debilitating.4–6
Some studies have shown that womenwith IC may have a
higher prevalence of several organisms in the urinarymicro-
biota of the lower urinary tract, even with negative culture
(for bacteria). In addition, the reports of a decrease in
symptoms following the administration of antibiotics in
some cases of IC suggest that bacteria may have a role in
the symptoms of this disease.7
Although there are several clinical trials to assess oral and
intravesical therapies for the syndrome, the treatment for IC
remains far from ideal.6 Moreover, many of the existing oral
treatments are ineffective in patients with IC, and patients
might require multimodal treatment to relieve symptoms.4
Recent studies have suggested that nitric oxide (NO) may
play a role in the etiology of IC. Nitric oxide is the product of
L-arginine oxidation and has many physiological functions,
but two are considered important in the bladder and, poten-
tially, in IC. First, it acts as an antagonist of smooth muscle
contraction, promoting muscle relaxation; and second, it
seems to inhibit the degranulation of mast cells, decreasing
the associated inflammatory reactions. Womenwith IC have
significantly less NO synthesis activity in their urine than
normal control subjects.8,9
Amitriptyline is an option frequently used to treat pa-
tients with IC. It has at least three major pharmacological
actions. It has central and peripheral anticholinergic action,
and it blocks the active transport system in the presynaptic
nerve ending, which is responsible for the reuptake of
serotonin and noradrenaline. The sedative properties may
be related to its antihistaminic properties and may explain
the potential benefits observed in patients with IC.6
Other drugs, such as gabapentin, are being studied with a
specific focus on pain treatment. Pentosan polysulfate sodium
(PPS) is the only FDA-approved oral therapy for IC. The
mechanism of action for PPS is not completely understood,
but a widely accepted theory is that it replaces the damaged
segments of the glycosaminoglycan layer, which protects the
bladder against the corrosive effects of urine and bacteria. It is
believed that intravesical therapy, comparedwith oral therapy
alone, may provide the benefit of establishing a higher drug
performed,weshould considerpentosanpolysulfateasoneof thebestoptionsoforal drugs
for the treatment of BPS symptoms. However, this drug is not an available option in Brazil.
Orally administered amitriptyline is an efficaciousmedical treatment for BPS, and it should
be the first treatment offered.
Resumo Cistite intersticial (IC), incluindo a síndrome da bexiga dolorosa (SBD), é uma doença
crônica e debilitante que afeta principalmente mulheres. É caracterizada por dor
pélvica associada à urgência miccional, frequência urinária, noctúria e exame cultural
de urina negativo, com citologia normal. A cistite intersticial pode ser suficientemente
severa para ter um efeito devastador na qualidade de vida, mas também pode estar
associada a sintomas moderados e menos debilitantes. Embora existam vários ensaios
clínicos para avaliar terapias orais e intravesicais, o tratamento para IC permanece
longe do ideal. Esta revisão sistemática avaliou ensaios clínicos randomizados publi-
cados sobre medicamentos orais usados para tratar sintomas de SBD. Este estudo foi
realizado de acordo com o método preferred reporting items for systematic reviews and
meta-analyses (PRISMA). Dois revisores independentes examinaram os estudos para
determinar sua inclusão ou exclusão e para realizar a análise metodológica. Os critérios
de inclusão foram: ensaios clínicos randomizados publicados entre abril de 1988 e abril
de 2016 que usaram medicações orais no tratamento dos sintomas da SBD ou CI. De
acordo com a revisão sistemática realizada, a melhor opção de medicação oral para o
tratamento dos SBD é o pentosano polissulfato sódico. No entanto, esta droga não está
disponível no Brasil. A amitriptilina administrada por via oral é um tratamento eficaz
para SBD e deve ser oferecida como primeira escolha.
Descritores
► síndrome da bexiga
dolorosa
► cistite intersticial
► terapia oral
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concentration directly into the bladder, with a minimal risk of
systemic side effects. Thus, the PPS instilled directly into the
bladder could accelerate the resolution of IC symptoms.4
The objective of this systematic review is to evaluate
published randomized clinical trials on oral medications
used to treat symptoms of BPS, analyzing group of patients,
interventions, comparisons and outcomes of each study.5
Methods
A systematic review was performed using the PubMed,
Embase and Lilacs databases. The following terms were
used to search clinical trials that included female patients:
interstitial cystitis or painful bladder syndrome or bladder
pain syndrome or pelvic pain and pharmacological treatment.
This study was performed according to the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) statement.10 Two independent reviewers screened
the studies to determine inclusion or exclusion and to
perform the methodological analysis.
The inclusion criteria comprised randomized studies pub-
lished between April of 1988 and April of 2016 that used oral
medications to treat symptoms of BPS or IC.We included trials
that compared an oral treatment for BPS versus another oral,
intravesical or placebo treatment. The oral medication must
have been used in at least one arm of the study and the
methodology must have been clearly described.
Studies that were not published in English, Portuguese or
Spanish and studies that did not show results related to the
symptoms of BPS or IC were excluded.
The articles were subdivided into groups according to the
drug used. The results of each group were assessed by com-
paring the initial assessment to thefinal clinical outcomedata.
All articles were scored according to the Jadad scale.11 The
Jadad scale consists of three topics, which are directly related
to bias reduction and are centered on internal validity. All
questions have a yes/no option. The Jadad Scale has a five-
point quality scale: three single points for “yes” responses
and two additional points for appropriate methods of ran-
domization and allocation concealment.11
Results
Initially, 45 articles were identified in the database search.
Twenty publications were fully analyzed, and from these
studies, 13 randomized studies were selected for inclusion.
The studiesweredivided into subgroups, according to thedrug
studied: 5 studies assessed PPS, 2 studies assessed amitripty-
line, 2 studies assessed L-arginine, and4 studies assessedother
drugs (sildenafil, antibiotics, cyclosporine, dimethyl sulfoxide
[DMSO] and PD-0299685). The study selection process is
illustrated in a PRISMA flowchart presented in ►Fig. 1.
L-Arginine
Two studies that used L-arginine to treat BPS were found.
Korting et al2 tested a dose of 1,500 mg daily for 3 months
compared with placebo. The four primary outcome measures
usedtoassess theeffectof L-arginine treatmenton IC symptoms
wereavoidingdiary, a secondaryoutcomemeasure, a symptom
score and a Likert scale. According to the intention-to-treat
Fig. 1 Flowchart demonstrating the process of searching, screening, and selecting eligible studies.
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(ITT) analysis, 22% of the patients (6 of 27) in the L-arginine
group, and 12% (3 of 26) of the ones in the placebo group
were clinically improved at the end of the trial (p ¼ 0.31). The
ITT analysis showed no significant differences between the
groups in the voiding diary results evaluating frequency and
nocturia, secondary outcome measure, symptom score or the
Likert scale. The trial was completed by 21 of 27 patients in the
L-arginine group, and 25 of 26 in the placebo group. According
to the protocol analysis, 29% (6 out of 21) of the patients in the
L-arginine group and 8% (2 out of 25) of those in the placebo
group were clinically improved by the end of the trial
(p ¼ 0.07). A Likert scale showed greater global improvement
in the L-arginine group (48%, 10 of 21) compared with the
placebo group (24%, 6 of 25) at 3 months (p ¼ 0.05), with a
decrease in pain intensity (p ¼ 0.041), and tendency toward
improvement in urgency (p ¼ 0.06) and frequency of pain
(p ¼ 0.09). Using an ITT analysis of the outcome measures,
there were no significant differences between the groups after
the initiation of L-arginine or placebo. According to the per-
protocol analysis, the Likert scale showed significant improve-
ment in the L-arginine group comparedwith theplacebogroup.
As per the Likert scale, the L-arginine group had significantly
greater improvement in pain intensity and in all symptoms
combined (global improvement) at 3 months. The ITT analysis
includes all patients, regardless of withdrawal from the trial for
assignedgroupanalysis.Theper-protocolanalysis includesonly
those patients who adhere to the protocol during the study.
According to the per-protocol analysis, the use of L-arginine
significantly decreased the IC pain intensity (p ¼ 0.04) and the
global scores on a Likert scale (p ¼ 0.05) (►Table 1).2
Cartledge et al8 tested a daily dose of 2,400 mgof L-arginine
for 4 weeks and compared the results with those of placebo.
The primary endpoint of the study was a change in the IC
symptoms index (ICSI) score. Therewasnodifferencebetween
the group receiving L-arginine and the placebo in the studied
outcomes (ICSI score, symptoms score and voiding diary). The
ICSI score recorded from patients after 4 weeks of L-arginine
usewas 7.5% lower than themean value calculated at baseline
(p < 0.05). Although lower than themean ICSI score recorded
from patients on placebo, the difference was not significant
(p ¼ 0.16), and even though the improvement in the ICSI score
over baseline after 4 weeks of treatment with L-arginine was
statistically significant, the effect was not considerably better
than that with placebo (►Table 1).8
Other Drugs
The following four treatments were tested: PD-0299685,
cyclosporine A, sildenafil and multiple antibiotics.
The PD-0299685 is an agonist of the α2-delta subunit of the
voltage-dependent calcium channel. The α2-delta subunit of
voltage- gated calcium ion channels mediates afferent pain
fibersand is implicated inchronicpain. There isa small number
of uncontrolled reports suggesting that, as the α2-delta ligand
may have efficacy in refractory genitourinary pain and IC/BPS.
Nickeletal3 testedPD-0299685atdailydosesof30and60 mg
and compared the results to those of the placebo group for a 12-
week period; PD-0299685 failed to show a significant benefit
over the placebo and presented poor tolerability (►Table 2).3
Sairanen et al9 compared a cyclosporine A (CyA) dose of
1.5mg/kg, twiceperday,with100 mgof PPS, 3 timesperday for
6 months. Cyclosporine A was superior to PPS in all clinical
studied outcome parameters measured at 6 months. The mic-
turition frequency in 24 hours was significantly reduced in the
CyA arm comparedwith the PPS arm. The clinical response rate
(according to global response assessment) was 75% for CyA
compared with 19% for PPS (p < 0.001). There were more
adverse events in the CyA arm than in the PPS arm. (►Table 2).9
Chen et al12 tested sildenafil at daily doses of 25 mg and
compared these results to those of a placebo for a 3-month
period. Sildenafil showed significant superiority over the
placebo on all studied outcomes (►Table 2).12
Warren et al7 tested the combination of using a 300 mg per
day dose of rifampicin for 18 weeks with a sequential therapy
of antibiotics, 3weeks each, using the followingdoses: 100 mg
doxycycline twice per day; 250 mg erythromycin four times
per day; 500 mg metronidazole four times per day; 300 mg
clindamycin four times per day; 500 mg amoxicillin three
times per day and 250 mg ciprofloxacin twice per day in
comparison to placebo. The treatment did not significantly
improve the symptoms, compared with placebo, and showed
significant increase in dropout and side effects (►Table 2).7
Amitriptyline
Two studies using amitriptyline to treat BPS were included
(►Table 3). Foster et al6 performed a study with 271 partic-
ipants, inwhich both groups received information on behavioral
modifications, and compared amitriptyline versus placebo.
The medication was increased on the sixth week from 10 to
75 mg/day. The primary outcome was the assessment of the
Table 1 Outcomes of L-arginine in the treatment of painful bladder syndrome
First Author/Year n Groups Outcomes
Measured
Results Significance
between
groups
Jadad
Scale11
score
Cartledge et al
(2000)8
16 L-arginine x placebo ICSI score
Voiding Diary
Significant improvement
compared with initial
assessment. No difference
between groups.
p ¼ 0.16 3
Korting et al
(1999)2
53 L-arginine x placebo Symptoms Score
Likert Scale
Voiding Diary
No difference
between groups.
p ¼ 0.31
(intention
to treat)
5
Abbreviation: ICSI, interstitial cystitis symptoms index.
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global response based on the improvement of symptoms after
12weeks of treatment. The subgroup of patients that received a
doseofat least50 mgamitriptylinedemonstratedasignificantly
higher response than that obtained with placebo (p < 0.01).6
Van Ophoven et al1 tested amitriptyline at a dose of 25 to
100 mg and compared these effects to placebo. There was
significant change in the symptoms score, and a significant
improvement in pain and urgency was observed when the
treated group was compared with placebo. The use of
amitriptyline for 4 months was considered safe and effective
for the treatment of IC.1
Pentosan Polysulfate Sodium
Five randomized studies assessed the use of PPS in the
treatment of symptoms of IC/BPS, and their most relevant
results are described in ►Table 4.
The studies included a total of 1,084 patients. The largest
serieswaspublishedbyNickel et al,4 in 2005, and included380
cases. Threedosesof PPSwere tested (300, 600 and900mg) for
32weeks. The ICSI score average improved significantly during
the 32 weeks for all dosages. Thus, there was relevant clinical
improvement with the three dosages. However, the treatment
duration appeared to be more important than the dosage.4
Mulholland et al13 compared the results of PPS use to
those of placebo over 3 months of treatment. Global im-
provement higher than 25% was reported by 28% of patients
treated with PPS and by only 13% of patients who received
placebo (p ¼ 0.03). In this study, PPS was considered as safe
and more effective than placebo.13
Sant et al14 published a study designed to assess PPS and
hydroxyzine. The primary outcome was the global response
assessment. The treatment response rate with hydroxyzine
was 31% and therewas a 20% response for the untreatedgroup
(p ¼ 0.26).With PPS, the responsewas 34%and in the untreat-
ed group it was 18% (p ¼ 0.064). The low global response rate
to PPS and hydroxyzine suggests that none of these therapies
can provide benefits to most patients with IC.14
Nickel et a.15 tested doses of 100 and 300 mg of PPS and
compared these effects to those of the placebo group for
24weeks. Therewasnodifferencebetweenthegroups receiving
PPS and placebo regarding the primary outcome (30% of reduc-
tion of ICSI total score from the initial to final assessment).15
David et al16 assessed 41 women diagnosed with IC who
received intravesical PPS associated with oral PPS or placebo
associated with oral PPS for 6 weeks. The use of intravesical
PPS combinedwith oral PPSwas the safest andmost effective
therapeutic option.16
The studies included were scored according to the Jadad
Scale. Only three studies received themaximum score on this
scale, which showed high quality; nine studies scored three
or lower and one study scored four.
Discussion
The product of L-arginine oxidation is NO. Although NO may
haveapotential effecton theetiologyofBPS, the clinical results
of L-arginine in the treatment of this pathologywere no better
than placebo.2,8 Among the drugs with very few studies in the Ta
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management of BPS, sildenafil at a low dose and CyA showed
promising initial results, but these results need to be verified
by further studies with larger groups of individuals.9,12
According to Foster et al,6 amitriptyline plus an education
and behavioral modification program did not significantly
improve the symptoms. The adverse effects were acceptable,
but theadherence totreatmentwithhigherdoseswas low. The
study also suggests that amitriptylinemay bebeneficial just in
the group that can achieve a daily dose of 50mg/day, although
this subgroupcomparisonwasnot specified inadvance.6 In the
study performedby vanOphoven et al,1 therewas an improve-
ment in symptoms, and it was also confirmed that amitripty-
line showed a significant improvement in the urinary urgency
symptom. These authors describe that, based on the results of
this study, they recommended using amitriptyline as a first-
line therapy for IC in their institution.1
With regard to PPS assessment, the studies showed hetero-
geneous outcomes. Three series included a dose of 300mg/day
in their assessments. In two of the series, this dose was
compared with placebo, and the results were conflicting. In
the study performed by Nickel et al (2014),15 there was no
difference between the group that received 300mg/day of PPS
and the group that received placebo on the primary outcome,
which was defined in this study as a 30% reduction of the
ICSI total score from the initial to final assessment. In the
series published by Mulholland et al,13 with the same dose of
300 mg/day, PPS was more effective than placebo.13,15
However, due to the limitations caused by the study design,
early termination, inclusion criteria and high dropout rate,
Nickel et al (2014)15 reported that theydonotbelieve that their
study can be used to justify the abandonmentof one of the few
medications with significant clinical trials in the treatment of
IC/BPS They also report that PPS is most likely the best
component of an overall therapeutic strategy as described in
the American Urological Association (AUA) guidelines.15
Although antihistamines are widely used in the treatment
of BPS, studies that assess their exclusive usewere not found in
our search. Only one study evaluating hydroxyzinewas found.
It was not possible to perform a meta-analysis based on
the assessed clinical trials due to the heterogeneity of the
published studies.
Conclusion
According to the systematic review performed, we should
consider PPS as one of the best options of oral drugs for the
treatment of BPS symptoms. However, this drug is not an
available option in Brazil. Orally administered amitriptyline
is an efficacious medical treatment for BPS and should be the
first treatment offered.
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